v3.26.3
SEGMENT REPORTING (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
USD ($)
Jun. 30, 2026
USD ($)
Mar. 31, 2026
USD ($)
Sep. 30, 2025
USD ($)
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Sep. 30, 2026
USD ($)
segment
Sep. 30, 2025
USD ($)
Segment Reporting [Abstract]                
Number of reportable segments | segment             1  
Segment Reporting [Line Items]                
Infusion services net revenue $ 1,493,529     $ 1,435,016     $ 4,286,583 $ 4,184,073
(Expense) Income:                
Depreciation and amortization expense (18,120)     (16,291)     (50,479) (48,278)
Interest expense, net (12,875)     (14,146)     (40,199) (41,824)
Equity in earnings of joint ventures 1,500     2,200     4,916 5,300
Other, net 1,037     (3,570)     2,273 (8,497)
Income tax expense (21,468)     (17,151)     (57,202) (52,303)
NET INCOME 57,433 $ 53,913 $ 45,343 51,816 $ 50,523 $ 46,742 156,689 149,081
Reportable Segment                
Segment Reporting [Line Items]                
Infusion services net revenue 1,466,761     1,411,051     4,209,545 4,115,240
Other revenue 26,768     23,965     77,038 68,833
Total Option Care Health revenue 1,493,529     1,435,016     4,286,583 4,184,073
(Expense) Income:                
Cost of net revenues - drugs (1,063,023)     (1,016,245)     (3,036,628) (2,953,923)
Salaries, benefits, and other employee expense (223,828)     (214,594)     (654,052) (632,481)
Other segment items (99,342)     (103,379)     (298,523) (302,986)
Depreciation and amortization expense (18,120)     (16,291)     (50,479) (48,278)
Interest expense, net (12,875)     (14,146)     (40,199) (41,824)
Equity in earnings of joint ventures 1,523     2,176     4,916 5,300
Other, net 1,037     (3,570)     2,273 (8,497)
Income tax expense (21,468)     (17,151)     (57,202) (52,303)
NET INCOME $ 57,433     $ 51,816     $ 156,689 $ 149,081